Evidence map›Paper›PMID 38681383›Full record

ArticleCureus2024

Sickle Cell Anomaly Meets Leukemic Challenge: A Case Report.

Shruti H Mandviya, Snehlata Hingway, Mayur Wanjari, Sukanya S Ingale, Isha Panbude, Atharvi Yembewar, Prachi Landge

Abstract readCase Reports
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shruti H MandviyaPathology and Laboratory Medicine, School of Allied Health Sciences, Datta Meghe Institute of Higher Education & Research, Wardha, IND.
Snehlata HingwayPathology, School of Allied Health Sciences, Datta Meghe Institute of Higher Education & Research, Wardha, IND.
Mayur WanjariResearch and Development, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education & Research, Wardha, IND.
Sukanya S IngalePathology, School of Allied Health Sciences, Datta Meghe Institute of Higher Education & Research, Wardha, IND.
Isha PanbudePathology, School of Allied Health Sciences, Datta Meghe Institute of Higher Education & Research, Wardha, IND.
Atharvi YembewarPathology, School of Allied Health Sciences, Datta Meghe Institute of Higher Education & Research, Wardha, IND.
Prachi LandgePathology, School of Allied Health Sciences, Datta Meghe Institute of Higher Education & Research, Wardha, IND.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This case report delves into the rare occurrence of sickle cell disease (SCD) and acute myeloid leukemia (AML) coexisting in a 36-year-old patient. The initial presentation, marked by escalating fatigue, pallor, and recurrent episodes initially attributed to sickle cell disease, unveiled an unexpected discovery of AML upon bone marrow examination. The diagnostic hurdles stemming from overlapping clinical features necessitated a thorough approach incorporating hematological, molecular, and imaging studies. Managing both conditions concurrently entailed navigating complexities addressed by a multidisciplinary team, tailoring chemotherapy regimens, and implementing personalized strategies to tackle complications associated with SCD. This case underscores the significance of tailored and comprehensive approaches in diagnosing and managing patients with overlapping hematological disorders. The insights gleaned from this instance contribute to the evolving comprehension of such intricate interplays, guiding future research endeavors and enhancing the care provided to patients simultaneously grappling with SCD and acute myeloid leukemia (AML). This case study investigates the unusual medical history of a 36-year-old male patient who concurrently has acute myeloid leukemia and sickle cell disease. Since childhood, the patient has endured severe anemia, necessitating frequent red blood cell transfusions or exchange blood therapy. Additionally, the patient was prescribed hydroxyurea (HU) for approximately 26 months.

Indexed as

acute myeloid leukemia (aml)bloodhemodialysis accesshydroxyureaprognosissickle cell disease

Identifiers

PMID38681383
PMCPMC11053231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.